261 related articles for article (PubMed ID: 18559613)
1. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Evers B; Schut E; van der Burg E; Braumuller TM; Egan DA; Holstege H; Edser P; Adams DJ; Wade-Martins R; Bouwman P; Jonkers J
Clin Cancer Res; 2010 Jan; 16(1):99-108. PubMed ID: 20008842
[TBL] [Abstract][Full Text] [Related]
3. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.
Martino J; Siri SO; Calzetta NL; Paviolo NS; Garro C; Pansa MF; Carbajosa S; Brown AC; Bocco JL; Gloger I; Drewes G; Madauss KP; Soria G; Gottifredi V
Elife; 2023 Apr; 12():. PubMed ID: 37073955
[TBL] [Abstract][Full Text] [Related]
5. Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
Guantay L; Garro C; Siri S; Pansa MF; Ghidelli-Disse S; Paviolo N; Racca A; Nicotra V; Radu C; Bocco JL; Felice R; Jansson KH; Remlinger K; Amador A; Stronach E; Coleman K; Muelbaier M; Drewes G; Gloger I; Madauss K; García M; Gottifredi V; Soria G
Drug Resist Updat; 2023 Mar; 67():100932. PubMed ID: 36706533
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.
Reisländer T; Lombardi EP; Groelly FJ; Miar A; Porru M; Di Vito S; Wright B; Lockstone H; Biroccio A; Harris A; Londoño-Vallejo A; Tarsounas M
Nat Commun; 2019 Jul; 10(1):3143. PubMed ID: 31316060
[TBL] [Abstract][Full Text] [Related]
7. A syngeneic variance library for functional annotation of human variation: application to BRCA2.
Hucl T; Rago C; Gallmeier E; Brody JR; Gorospe M; Kern SE
Cancer Res; 2008 Jul; 68(13):5023-30. PubMed ID: 18593900
[TBL] [Abstract][Full Text] [Related]
8. A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer.
Lee E; Archasappawat S; Ji K; Pena J; Fernandez-Vega V; Gangaraju R; Beesabathuni NS; Kim MJ; Tian Q; Shah PS; Scampavia L; Spicer TP; Hwang CI
Cell Death Dis; 2023 Sep; 14(9):620. PubMed ID: 37735513
[TBL] [Abstract][Full Text] [Related]
9. A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer.
Lee E; Archasappawat S; Ji K; Pena J; Fernandez-Vega V; Gangaraju R; Beesabathuni NS; Kim MJ; Tian Q; Shah P; Scampavia L; Spicer T; Hwang CI
bioRxiv; 2023 May; ():. PubMed ID: 37398312
[TBL] [Abstract][Full Text] [Related]
10. Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.
Kim H; Aliar K; Tharmapalan P; McCloskey CW; Kuttanamkuzhi A; Grünwald BT; Palomero L; Mahendralingam MJ; Waas M; Mer AS; Elliott MJ; Zhang B; Al-Zahrani KN; Langille ER; Parsons M; Narala S; Hofer S; Waterhouse PD; Hakem R; Haibe-Kains B; Kislinger T; Schramek D; Cescon DW; Pujana MA; Berman HK; Khokha R
Cell Rep; 2023 Nov; 42(11):113382. PubMed ID: 37883228
[No Abstract] [Full Text] [Related]
11. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
12. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Fong PC; Boss DS; Yap TA; Tutt A; Wu P; Mergui-Roelvink M; Mortimer P; Swaisland H; Lau A; O'Connor MJ; Ashworth A; Carmichael J; Kaye SB; Schellens JH; de Bono JS
N Engl J Med; 2009 Jul; 361(2):123-34. PubMed ID: 19553641
[TBL] [Abstract][Full Text] [Related]
14. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
15. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
16. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR
Cancer Res; 2009 May; 69(9):3850-5. PubMed ID: 19383921
[TBL] [Abstract][Full Text] [Related]
18. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
